ABSTRACT
Mitochondrial dysfunction has been established as a common feature of neurodegenerative disorders that contributes to disease pathology by causing impaired cellular energy production. Mitochondrial molecules released into the extracellular space following neuronal damage or death may also play a role in these diseases by acting as signaling molecules called damage-associated molecular patterns (DAMPs). Mitochondrial DAMPs have been shown to initiate proinflammatory immune responses from nonneuronal glial cells, including microglia and astrocytes; thereby, they have the potential to contribute to the chronic neuroinflammation present in these disorders accelerating the degeneration of neurons. In this review, we highlight the mitochondrial DAMPs cytochrome c (CytC), mitochondrial transcription factor A (TFAM), and cardiolipin and explore their potential role in the central nervous system disorders including Alzheimer's disease and Parkinson's disease, which are characterized by neurodegeneration and chronic neuroinflammation.
Subject(s)
Inflammation/immunology , Mitochondria/metabolism , Mitochondria/pathology , Neurodegenerative Diseases/immunology , Animals , Cytochromes c/metabolism , DNA-Binding Proteins/metabolism , Humans , Inflammation/metabolism , Mitochondrial Proteins/metabolism , Neurodegenerative Diseases/metabolism , Transcription Factors/metabolismABSTRACT
Cardiolipin is a mitochondrial membrane phospholipid with several well-defined metabolic roles. Cardiolipin can be released extracellularly by damaged cells and has been shown to affect peripheral immune functions. We hypothesized that extracellular cardiolipin can also regulate functions of microglia, the resident immune cells of the central nervous system (CNS). We demonstrate that extracellular cardiolipin increases microglial phagocytosis and neurotrophic factor expression, as well as decreases the release of inflammatory mediators and cytotoxins by activated microglia-like cells. These results identify extracellular cardiolipin as a potential CNS intercellular signaling molecule that can regulate key microglial immune functions associated with neurodegenerative diseases.
Subject(s)
Cardiolipins/physiology , Microglia/immunology , Microglia/metabolism , Animals , Cardiolipins/metabolism , Cell Culture Techniques , Cell Line , Central Nervous System/metabolism , Cytokines/metabolism , Humans , Intercellular Signaling Peptides and Proteins/metabolism , Lipopolysaccharides/metabolism , Macrophages , Mice , Mice, Inbred C57BL , Nerve Growth Factors/metabolism , Neurodegenerative Diseases/metabolism , Phagocytosis , Signal Transduction/physiologyABSTRACT
BACKGROUND: Alzheimer's Disease (AD) and Parkinson's Disease (PD) are among the most common causes of dementia, which increasingly contribute to morbidity and mortality worldwide. A common hallmark in the pathogenesis of these two diseases is neuroinflammation, which is initially triggered by the presence of pathological structures associated with these disorders. Chronic neuroinflammation is sustained by persistent and aberrant microglial activation in the brain, which results in damage and death of neighboring cells, including neurons and glial cells. Two types of risk factors contribute to the development of AD and PD: non-modifiable risk factors and modifiable risk factors. Non-modifiable risk factors include genetic susceptibility that increases an individual's risk of developing the disease, whereas modifiable risk factors include a wide variety of health- and lifestyle-related factors that may be altered by changing individual behaviors. METHOD: Ovid Medline and PubMed databases were used to perform an ordered search of the peerreviewed research literature described in this review. RESULTS: This review focuses on four modifiable risk factors including physical inactivity, vascular disease-related conditions, obesity and type two diabetes mellitus, all of which have been identified as risk factors for the development of AD and PD. CONCLUSION: We highlight that control of the modifiable risk factors is a valid approach for managing the increased incidence of AD and PD. We describe neuroinflammatory mechanisms, which are common to AD and PD that may link both these neurodegenerative diseases with the four common modifiable risk factors. Understanding neuroinflammatory mechanisms could help identify novel therapeutic targets for combating these neurodegenerative diseases.
Subject(s)
Alzheimer Disease/prevention & control , Brain/physiopathology , Encephalitis/therapy , Parkinson Disease/prevention & control , Age Factors , Alzheimer Disease/diagnosis , Alzheimer Disease/epidemiology , Alzheimer Disease/physiopathology , Animals , Brain/immunology , Brain/metabolism , Diabetes Mellitus, Type 2/epidemiology , Diet, Healthy , Encephalitis/diagnosis , Encephalitis/epidemiology , Encephalitis/physiopathology , Exercise , Healthy Aging , Humans , Incidence , Inflammation Mediators/metabolism , Obesity/epidemiology , Parkinson Disease/diagnosis , Parkinson Disease/epidemiology , Parkinson Disease/physiopathology , Protective Factors , Risk Assessment , Risk Factors , Risk Reduction Behavior , Sedentary Behavior , Signal Transduction , Vascular Diseases/epidemiologyABSTRACT
Cardiolipin, an anionic phospholipid found primarily in the inner mitochondrial membrane, has many well-defined roles within the peripheral tissues, including the maintenance of mitochondrial membrane fluidity and the regulation of mitochondrial functions. Within the central nervous system (CNS), cardiolipin is found within both neuronal and non-neuronal glial cells, where it regulates metabolic processes, supports mitochondrial functions, and promotes brain cell viability. Furthermore, cardiolipin has been shown to act as an elimination signal and participate in programmed cell death by apoptosis of both neurons and glia. Since cardiolipin is associated with regulating brain homeostasis, the modification of its structure, or even a decrease in the overall levels of cardiolipin, can result in mitochondrial dysfunction, which is a characteristic feature of many diseases. In this review, we outline the various functions of cardiolipin within the cells of the CNS, including neurons, astrocytes, microglia, and oligodendrocytes. In addition, we discuss the role cardiolipin may play in the pathogenesis of the neurodegenerative disorders Alzheimer's disease and Parkinson's disease, as well as traumatic brain injury.